Ir para o conteúdo principal

Celldex Therapeutics (NASDAQ: CLDX) — Perfil da empresa, notícias e dados financeiros

Logo de Celldex Therapeutics
CLDX Celldex Therapeutics
Celldex Therapeutics primary media
Perfil da empresa

Celldex Therapeutics

Celldex Therapeutics (NASDAQ:CLDX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer and other difficult-to-treat diseases. Drawing on a deep expertise in immunology, Celldex is pioneering a robust pipeline of potential therapies designed to enhance the body's natural defenses against disease. The company's projects span from early-stage research to phase 3 clinical trials, with key focuses on precision medicine and immune therapeutics. Through strategic collaborations and cutting-edge research, Celldex aims to improve patient outcomes and advance the field of medicine. Their objective is not only to deliver life-changing treatments to patients in need but also to lead the way in discovering and developing new pathways for treating cancer and immune-related diseases.

Resumo

Public USParticipação acionária
1983Ano de fundação
189Funcionários
Hampton, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Celldex Therapeutics

  • CDX-0159: A monoclonal antibody targeting KIT for chronic inducible urticaria, currently in Phase 2 clinical trials.
  • CDX-1140: An immune activating agonist targeting CD40, involved in Phase 1 trials for solid tumors and B-cell malignancies.
  • CDX-527: A combination of an anti-PD-L1 and an anti-CD27 in one molecule, designed for various cancers, in Phase 1 trials.
  • Glembatumumab vedotin: An antibody-drug conjugate targeting gpNMB for advanced melanoma and breast cancer, previously in clinical trials.
  • Varlilumab: An agonist antibody targeting CD27 to activate the immune system against cancer, involved in clinical research.
  • CDX-301: A recombinant human Flt3 ligand aimed at enhancing stem cell and immune restoration, used in various clinical settings.

equipe executiva do Celldex Therapeutics

  • Anthony S. MarucciFounder, President, CEO & Director
  • Tibor KelerFounder, Chief Scientific Officer & Executive VP
  • Sam MartinSenior VP, CFO, Secretary & Treasurer
  • Elizabeth CrowleyChief Product Development Officer & Senior VP
  • Margo Heath-ChiozziSenior Vice President of Regulatory Affairs
  • Joseph P. SchlessingerCo-Founder & Member of Scientific Advisory Board
  • Sarah CavanaughSenior Vice President of Corporate Affairs & Administration
  • Freddy A. JimenezSenior VP & General Counsel
  • Ronald A. PepinChief Business Officer & Senior VP
  • Diane C. YoungSenior VP & Chief Medical Officer

Últimas notícias sobre a Celldex Therapeutics

Principais indicadores financeiros

Resultados divulgados pela Celldex Therapeutics, em USD.

Cap. de mercado
2,3 bi
Receita (TTM)
158 mil
P/L
—
LPA (diluído, TTM)
-4.3
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Celldex Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
1,5 mi-287,4 mi-258,8 mi
7 mi-195,1 mi-157,9 mi
6,9 mi-154,5 mi-141,4 mi
2,4 mi-115,2 mi-112,3 mi